Luye Pharma Group Ltd (2186)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 22 Oct 2026
Key indicators
| Last close | HKD 1.580 |
|---|---|
| 52-week range | 1.580 – 3.270 |
| Return, 1 month / 3 months | −14.1% / −25.1% |
| Return, 1 year / 3 years | −50.8% / −53.7% |
| Trend | Below its 200-day average |
| RSI (14) | 30 |
| Volatility (1 year) | 45.2% |
| Worst drawdown (1 year) | -56.0% |
| Average daily value traded | 55.46M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Luye Pharma Group is a pharmaceutical company based in China that develops, manufactures and markets prescription medicines. Its work spans treatments for cancer, disorders of the central nervous system and other chronic conditions, and it also develops advanced drug delivery technologies such as liposomes and microspheres that help control how a medicine is released in the body. The company serves hospitals and healthcare providers, mainly in China, and also sells its products in other markets around the world.
On this site Luye Pharma Group Ltd appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 2186, with prices in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Luye Pharma Group Ltd (2186) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 1.580 on 22 October 2026.
Its price-based Market X-Ray is 41 out of 100 (a weak price profile), ranking 1,687 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 50.8% and over the last three months it fell 25.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 27 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -31.1% | ||
| From 52-week high | -51.2% | ||
| Momentum | 17 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -25.1% | ||
| 6-month return | -43.0% | ||
| 12-month return, skipping the last month | -42.7% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 45.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -56.0% | ||
| Liquidity | 87 · Strong | Trades actively. | |
| Average daily value traded | 55.46M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −8.1% |
|---|---|
| 1 month | −14.1% |
| 3 months | −25.1% |
| 6 months | −43.0% |
| 1 year | −50.8% |
| 3 years | −53.7% |
| 5 years | −59.5% |
Signals
| 50-day / 200-day average | 1.880 / 2.292 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.072 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jun 2020 | HKD 0.0600 |
| 9 Sep 2019 | HKD 0.0670 |
| 14 Jun 2019 | HKD 0.0650 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.